Published in Br J Clin Pharmacol on February 01, 2005
Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother (2011) 1.12
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis (2014) 1.07
Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J (2012) 1.00
Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother (2012) 0.98
Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother (2010) 0.97
Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Br J Clin Pharmacol (2015) 0.94
Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Chemother (2012) 0.94
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol (2014) 0.92
Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet (2009) 0.88
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents Chemother (2012) 0.84
Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects. Malar J (2009) 0.83
Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study. Clin Ther (2011) 0.82
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children. Br J Clin Pharmacol (2016) 0.81
Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction. Antimicrob Agents Chemother (2015) 0.79
Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol (2015) 0.78
Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model. Br J Clin Pharmacol (2007) 0.78
A Semi-Physiological Population Model to Quantify the Effect of Hematocrit on Everolimus Pharmacokinetics and Pharmacodynamics in Cancer Patients. Clin Pharmacokinet (2016) 0.76
Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance). Br J Clin Pharmacol (2014) 0.76
Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children. J Antimicrob Chemother (2016) 0.75
Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother (2014) 0.75
Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children. Antimicrob Agents Chemother (2017) 0.75
An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn (2017) 0.75
A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. J Pharm Sci (2017) 0.75
Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87
Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm (1992) 3.97
Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol (1998) 3.53
Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients. Trans R Soc Trop Med Hyg (1996) 1.90
Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos (1998) 1.67
Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents (1999) 1.55
Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol (1999) 1.47
Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther (1998) 1.46
Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol (1996) 1.35
The regulation of cytochrome P-450 gene expression. Annu Rev Pharmacol Toxicol (1986) 1.28
Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci (1999) 1.25
Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol (1999) 1.21
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother (2002) 1.18
Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria. Antimicrob Agents Chemother (1999) 1.15
Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm Drug Dispos (1998) 1.13
Use of saliva and capillary blood samples as substitutes for venous blood sampling in pharmacokinetic investigations of artemisinin. Eur J Clin Pharmacol (2000) 1.09
Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther (1998) 1.08
A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin Pharmacol (1999) 1.05
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol (1995) 1.01
Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. Br J Clin Pharmacol (2001) 0.98
Single-dose, comparative study of venous, capillary and salivary artemisinin concentrations in healthy, male adults. Am J Trop Med Hyg (1997) 0.95
Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci (1996) 0.95
High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos (1999) 0.94
Direct analysis of artemisinin in plasma and saliva using coupled-column high-performance liquid chromatography with a restricted-access material pre-column. J Chromatogr B Biomed Sci Appl (2000) 0.91
Induction of drug-metabolizing enzymes by xenobiotics. Xenobiotica (1990) 0.85
Time-dependent kinetics. V: Time course of drug levels during enzyme induction (one-compartment model). J Pharmacokinet Biopharm (1979) 0.78
Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J (2011) 4.60
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J (2009) 3.99
Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn (2007) 3.00
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol (2007) 2.68
Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res (2007) 2.51
Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn (2008) 2.50
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol (2002) 2.44
Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol (2002) 2.43
Handling data below the limit of quantification in mixed effect models. AAPS J (2009) 2.11
Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother (2004) 2.08
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother (2008) 1.95
Pitfalls in estimating piperaquine elimination. Antimicrob Agents Chemother (2005) 1.79
Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci (2002) 1.72
Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn (2008) 1.59
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res (2011) 1.57
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst (2006) 1.48
Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol (2012) 1.48
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol (2002) 1.38
Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments. Antimicrob Agents Chemother (2006) 1.36
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol (2006) 1.31
Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res (2002) 1.30
Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother (2010) 1.27
PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Programs Biomed (2012) 1.27
Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED. J Pharmacokinet Pharmacodyn (2004) 1.24
Models for time-varying covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol (2004) 1.22
Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn (2002) 1.19
The influence of food on the pharmacokinetics of piperaquine in healthy Vietnamese volunteers. Acta Trop (2008) 1.19
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother (2002) 1.18
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. Eur J Clin Pharmacol (2003) 1.18
Assessment of type I error rates for the statistical sub-model in NONMEM. J Pharmacokinet Pharmacodyn (2002) 1.17
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn (2007) 1.16
Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH. Eur J Endocrinol (2009) 1.16
Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models. AAPS J (2012) 1.16
Semiparametric distributions with estimated shape parameters. Pharm Res (2009) 1.15
Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother (2012) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Performance in population models for count data, part I: maximum likelihood approximations. J Pharmacokinet Pharmacodyn (2009) 1.13
Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. Br J Clin Pharmacol (2005) 1.09
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther (2002) 1.08
Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther (2003) 1.07
Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res (2006) 1.06
A fast method for testing covariates in population PK/PD Models. AAPS J (2011) 1.05
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol (2007) 1.04
Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol (2003) 1.04
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother (2013) 1.03
The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data. J Pharmacokinet Pharmacodyn (2008) 1.01
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults. J Clin Pharmacol (2006) 1.01
Modelling overdispersion and Markovian features in count data. J Pharmacokinet Pharmacodyn (2009) 1.01
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Mechanistic models for myelosuppression. Invest New Drugs (2003) 1.00
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models. AAPS J (2012) 0.99
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics (2008) 0.99
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol (2011) 0.98
A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother (2012) 0.97
An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol (2007) 0.97
A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J (2012) 0.97
Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. Br J Clin Pharmacol (2004) 0.96
Shrinkage in nonlinear mixed-effects population models: quantification, influencing factors, and impact. AAPS J (2012) 0.96
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin Cancer Res (2004) 0.96
An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol (2007) 0.96
Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol (2015) 0.96
Evaluation of the nonparametric estimation method in NONMEM VI. Eur J Pharm Sci (2008) 0.95
Application of population pharmacokinetics to cladribine. BMC Pharmacol (2005) 0.95
Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients. J Pharmacokinet Pharmacodyn (2010) 0.95
Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother (2011) 0.95
Pharmacokinetics and renal excretion of desmopressin after intravenous administration to healthy subjects and renally impaired patients. Br J Clin Pharmacol (2004) 0.94
Knowledge about sexually transmitted diseases in women among primary care physicians. Sex Transm Dis (2005) 0.94
Modelling a spontaneously reported side effect by use of a Markov mixed-effects model. J Pharmacokinet Pharmacodyn (2005) 0.94
Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm Res (2006) 0.94
A Phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res (2002) 0.94
Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. Br J Clin Pharmacol (2008) 0.93
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. Br J Clin Pharmacol (2002) 0.93
An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers. J Clin Pharmacol (2009) 0.92
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy. AAPS J (2011) 0.92
Simultaneous optimal experimental design on dose and sample times. J Pharmacokinet Pharmacodyn (2009) 0.92
Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer. Eur J Clin Pharmacol (2014) 0.92
Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis. Clin Pharmacol Ther (2005) 0.92
Modeling of red blood cell life-spans in hematologically normal populations. J Pharmacokinet Pharmacodyn (2012) 0.92
Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol (2003) 0.90
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol (2002) 0.90
Artemisinin and CYP2A6 activity in healthy subjects. Eur J Clin Pharmacol (2007) 0.90
Zinc supplementation partially prevents renal pathological changes in diabetic rats. J Nutr Biochem (2009) 0.89
Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol (2003) 0.89
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res (2007) 0.89
An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol (2009) 0.89
Pharmacokinetic/pharmacodynamic modelling in oncological drug development. Basic Clin Pharmacol Toxicol (2005) 0.89
A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects. J Pharmacokinet Pharmacodyn (2013) 0.88
Comparison of proportional and differential odds models for mixed-effects analysis of categorical data. J Pharmacokinet Pharmacodyn (2008) 0.88
Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model. Invest New Drugs (2009) 0.88
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol (2005) 0.87
A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J Clin Pharmacol (2010) 0.87
Population pharmacokinetic modeling and deconvolution of enantioselective absorption of eflornithine in the rat. J Pharmacokinet Pharmacodyn (2013) 0.87
A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A. Br J Clin Pharmacol (2013) 0.87
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol (2009) 0.86